INTERNATIONAL JOURNAL OF OBESITY, published by SpringerNature, stands as a premier multidisciplinary platform for research in the fields of Endocrinology, Diabetes and Metabolism, Nutrition and Dietetics, as well as Miscellaneous Medicine. With a remarkable impact, the journal is consistently positioned in the Q1 category across these critical areas, underscoring its significance in advancing the understanding of obesity and its related health outcomes. Established in 1977 and covering a broad spectrum of studies until 2024, it boasts a notable Scopus Rank reflecting its influential contributions to the scientific community, including a rank of 14 out of 140 in Nutrition and Dietetics. The INTERNATIONAL JOURNAL OF OBESITY is not just a repository of knowledge but a vital resource for researchers, clinicians, and students aiming to explore the complexities of obesity and develop evidence-based interventions. Despite not being an open-access journal, its rigorous peer-reviewed articles remain accessible to those within academic institutions, facilitating an essential dialogue among professionals dedicated to this critical global health issue.

The European Journal of Heart Failure, published by Wiley, is a premier international journal dedicated to advancing the field of cardiology, specifically focusing on heart failure research and clinical practices. With an impressive impact factor and ranked in the top 1% of journals in Cardiology and Cardiovascular Medicine according to Scopus rankings (Rank #7/387, Percentile 98th), this journal serves as a vital resource for researchers, clinicians, and students alike. Spanning from 1999 to 2024, the journal has established itself as a cornerstone for innovative research, comprehensive reviews, and clinical insights, fostering a deeper understanding of heart failure mechanisms, management, and treatment strategies. Although not an open-access journal, the European Journal of Heart Failure remains committed to disseminating high-quality, peer-reviewed content that contributes significantly to the global cardiovascular community. Located in the United States at 111 River St, Hoboken, NJ 07030-5774, it continues to play an essential role in shaping the future of heart failure management.

JOURNAL OF HUMAN HYPERTENSION, a prominent publication in the field of internal medicine, is dedicated to advancing the understanding of hypertension and its implications for human health. Published by SPRINGERNATURE in the United Kingdom, this esteemed journal has been a vital resource for researchers and clinicians since its inception in 1987, with a continuous commitment to disseminating high-quality, peer-reviewed research. With an impressive Q2 category rank in Internal Medicine and a Scopus rank of 53 out of 167, it occupies a crucial position within the academic community, reaching a 68th percentile ranking that underscores its significance. The journal aims to provide a platform for innovative studies and reviews, fostering knowledge that bridges basic science, clinical practice, and public health. Although it does not currently offer open access, it remains accessible through institutional subscriptions, ensuring that vital information about hypertension is available to a broad spectrum of healthcare professionals and researchers. Explore the critical findings and groundbreaking research published in the JOURNAL OF HUMAN HYPERTENSION to stay at the forefront of hypertension studies.

Clinical Hypertension is a premier journal dedicated to advancing the field of hypertension and cardiovascular health, published by SpringerNature. Since its transition to an Open Access model in 2014, the journal has opened doors for researchers globally to share their findings without barriers, aiming to foster collaboration and innovation in this vital area of medicine. With a current impact factor that positions it in the Q2 quartile for both Cardiology and Cardiovascular Medicine and Internal Medicine, Clinical Hypertension is recognized for its scholarly contributions, reflected in its Scopus rankings (Rank #100/387 in Cardiology and Rank #52/167 in Internal Medicine), which place it in the top percentiles of these competitive fields. Covering a diverse range of topics within hypertension research, it serves as an essential resource for clinicians, researchers, and students alike, promising to keep its audience informed of the latest developments and breakthroughs from its inception in 2017 through to 2024.

Asian Biomedicine, published by WALTER DE GRUYTER GMBH, serves as a crucial platform for disseminating pioneering research in the field of biomedical sciences. Established in 2008, this journal has carved its niche in the landscape of academic publishing, concentrating on a diverse array of topics within biochemistry, genetics, and molecular biology, as well as medicine. Though it currently holds a Q4 ranking in its category, it is dedicated to fostering academic discussions and advancing knowledge among researchers, professionals, and students alike. While the journal features a variety of access options, it is committed to ensuring that its content remains relevant and impactful, with an emphasis on the latest developments and research trends. The editorial board encourages submissions that address pressing biomedical issues, thus empowering contributors to engage meaningfully with the scientific community. With a broad international scope and a focus on quality, Asian Biomedicine is poised to play an increasingly important role in the advancement of biomedical research in Asia and beyond.

Journal of Clinical Hypertension, published by WILEY, is a leading open-access journal focused on advancing the understanding and treatment of hypertension and related cardiovascular conditions. With an ISSN of 1524-6175 and an E-ISSN of 1751-7176, the journal provides a vital platform for researchers, healthcare professionals, and students alike to disseminate high-quality, peer-reviewed research. Since transitioning to open access in 2021, it has increased its reach and accessibility, ensuring critical information is available to a broader audience. The journal holds an impressive position in the Scopus ranks, nestled within the Q2 quartile across key disciplines including Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism, and Internal Medicine, indicating a strong impact on the scientific community. With articles converging from 2001 to 2024, it not only highlights contemporary developments but also contributes to the ongoing dialogue in the field. Researchers are encouraged to submit their findings on hypertension, treatment methodologies, and epidemiology to further enhance the collective knowledge in this crucial area of health.

Cardiology Research and Practice is a leading academic journal dedicated to advancing knowledge in the fields of cardiology and cardiovascular medicine. Published by HINDAWI LTD, this journal has been an inclusive platform for open access research since 2009, facilitating the dissemination of high-quality studies that contribute to the global scientific community. With an impact factor placing it in Q2 of its category in 2023, it underscores its importance in delivering innovative insights and discoveries that shape clinical practices and policies. The journal covers a broad scope of topics including, but not limited to, cardiovascular disease prevention, innovative treatment modalities, and emerging technologies, appealing to researchers, healthcare professionals, and students alike. Located in the United States with its international reach, Cardiology Research and Practice serves as a critical resource for those dedicated to improving patient outcomes and advancing the field of cardiology.

Rheumatology & Autoimmunity, published by WILEY, is an emerging academic journal that delves into the intricacies of rheumatological diseases and autoimmune disorders, providing a critical platform for researchers and practitioners within the field. With an ISSN of 2767-1410 and E-ISSN 2767-1429, the journal aims to disseminate cutting-edge research in both clinical and laboratory settings, enhancing knowledge and understanding among professionals and scholars. Although currently classified in Q4 for Immunology and Allergy, and Q3 for Internal Medicine and Rheumatology as of 2023, the journal is positioned for growth and greater visibility in the scientific community. The three-year publishing span from 2021 to 2024 signifies a commitment to addressing contemporary issues and fostering collaboration among various disciplines related to immunology. As an open access journal, it provides wide accessibility, ensuring that groundbreaking research is available to a broad audience. This journal is poised to become a vital resource for those dedicated to advancing the understanding and treatment of autoimmune conditions.

JOURNAL OF HYPERTENSION, published by Lippincott Williams & Wilkins, stands at the forefront of cardiovascular research, serving as a premier platform for the dissemination of knowledge in hypertension and related cardiovascular conditions. With an impressive impact factor, this esteemed journal is recognized in Q1 quartile across multiple categories, including Cardiology, Internal Medicine, and Physiology as of 2023, firmly establishing its significance within the academic community. The journal has been a reliable source of cutting-edge research since its inception in 1983, with continued publication through 2024. Researchers can expect a rigorous peer-review process and a diverse array of articles that include original research, reviews, and clinical studies aimed at enhancing the understanding and management of hypertension. Although it is not an open-access journal, the JOURNAL OF HYPERTENSION remains invaluable to clinicians, researchers, and students dedicated to advancing the field of cardiovascular health.

Clinica e Investigacion en Arteriosclerosis is a premier academic journal dedicated to the field of cardiology and cardiovascular medicine, published by ELSEVIER. With its ISSN 0214-9168 and E-ISSN 1578-1879, the journal aims to disseminate high-quality research and innovations in the understanding and treatment of arterial diseases, contributing significantly to both clinical practices and pharmacological advancements. Established in 2007 and continuing into 2024, the journal has garnered recognition with a notable Q3 categorization in both Cardiology and Cardiovascular Medicine and Pharmacology (medical) for 2023, reflecting its impact in the academic community. Researchers and healthcare professionals utilizing this journal will find a diverse range of articles exploring novel therapeutic strategies and epidemiological data, making it an essential resource for advancing knowledge and practice in cardiovascular health. While it does not operate as an open-access journal, the findings published in Clinica e Investigacion en Arteriosclerosis are pivotal for understanding current trends and future directions in cardiovascular research.